A groundbreaking study published on September 17, 2025, in JAMA Dermatology sheds new light on nicotinamide’s real-world effectiveness by leveraging the extensive Veterans Affairs Corporate Data Warehouse. This data repository contains comprehensive medical records, allowing researchers to track the usage of nicotinamide prescribed through the VA formulary and its impact on skin cancer diagnoses. By analyzing the medical histories of over 33,800 veterans, the research team sought to quantify the degree to which nicotinamide administration at a dose of 500 milligrams twice daily for more than 30 days influenced the incidence of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), the two most common forms of non-melanoma skin cancers.

The study cohort consisted of 12,287 patients who were treated with nicotinamide and 21,479 patients who were not. The comparison revealed a compelling overall 14% reduction in the risk of developing new skin cancers in those receiving nicotinamide. Significantly, the protective effect was substantially amplified among patients who initiated nicotinamide after their first skin cancer diagnosis, with risk reduction escalating to 54%. This suggests a potent role for nicotinamide in mitigating subsequent carcinogenic events if introduced early during the patient’s clinical course. The data also demonstrated that the benefit diminished when nicotinamide therapy was started following multiple skin cancer occurrences.

Delving deeper into the cellular pathology, the researchers observed that nicotinamide’s impact was particularly pronounced for squamous cell carcinoma. This subtype is known for its aggressive nature and propensity for metastasis, highlighting nicotinamide’s potential in addressing not only skin cancer prevention but potentially modifying progression risk. The biochemical basis for these effects resides in nicotinamide’s role in enhancing cellular energy metabolism, promoting DNA repair, and mitigating ultraviolet-induced immunosuppression, which collectively converge to inhibit carcinogenesis in epidermal tissues.

Despite these promising findings, clinical guidelines for nicotinamide initiation lack consensus, with recommendations varying widely. Dr. Lee Wheless, MD, PhD, assistant professor of Dermatology and Medicine at Vanderbilt University Medical Center and staff physician at the VA Tennessee Valley Healthcare System, emphasizes that the new evidence could catalyze a paradigm shift. According to Dr. Wheless, the data advocates for earlier prophylactic use of nicotinamide, potentially at the stage of the first skin cancer, rather than waiting for patients to accumulate multiple lesions. Nonetheless, there remains a critical need to refine patient selection, as nearly half of individuals with a history of skin cancer do not go on to develop multiple tumors, and thus may not derive equivalent benefit from chemoprevention.

The study also ventured into the nuanced domain of immunocompromised populations, specifically solid organ transplant recipients, who experience dramatically increased skin cancer risk attributable to lifelong immunosuppressive therapy. Among the 1,334 transplant patients assessed, nicotinamide did not yield a statistically significant reduction in overall skin cancer occurrence. However, there was an intriguing signal suggesting that early use of nicotinamide might reduce instances of cutaneous squamous cell carcinoma in this high-risk group. This finding warrants further exploration, as immunosuppression profoundly alters skin carcinogenesis pathways and may modulate the response to preventive interventions.

At the molecular level, nicotinamide serves as a precursor to nicotinamide adenine dinucleotide (NAD+), a pivotal coenzyme involved in redox reactions and crucial for energy production and cellular repair mechanisms. By replenishing NAD+ pools, nicotinamide enhances the capacity of keratinocytes to repair ultraviolet radiation-induced DNA damage, thereby preventing mutations that drive malignant transformation. Moreover, nicotinamide’s anti-inflammatory properties counteract UV-induced immunosuppression, preserving skin immune surveillance against emerging tumor cells.

The clinical implications of this research are far-reaching. If nicotinamide can indeed halve the risk of subsequent skin cancers when administered after the initial tumor, this intervention could significantly reduce the morbidity associated with repeated surgical excisions, healthcare costs, and the psychological burden borne by patients. Wider adoption of nicotinamide as a standard element of skin cancer preventive care could also fuel novel therapeutic avenues combining nutritional supplementation with established dermatological treatments.

It is important to note that the research was funded by the Department of Veterans Affairs and involved multidisciplinary collaboration among Vanderbilt University Medical Center researchers, including Katyln Knox, Rachel Weiss, Siwei Zhang, PhD, Lydia Yao, MS, Yaomin Xu, PhD, and Kyle Maas. Dr. Wheless received support from a VA grant (IK2CX002452), underscoring the institutional commitment to advancing skin cancer prevention in veteran populations.

Looking forward, unanswered questions remain regarding the optimal duration of nicotinamide therapy, potential long-term side effects, and whether specific genetic or phenotypic profiles can predict individual responsiveness. Additionally, the delivery method and dosage warrant optimization to balance efficacy and compliance. Future randomized controlled trials with broader, ethnically diverse cohorts could illuminate these facets and facilitate evidence-based clinical guidelines.

While nicotinamide’s accessibility as an over-the-counter supplement offers advantages in cost and convenience, it also poses challenges for tracking usage and outcomes outside formal healthcare systems. The innovative approach of analyzing electronic medical records, as demonstrated in the VA study, provides a powerful template for observational pharmacoepidemiology that could be extended to other nutritional and preventive interventions.

In summary, this landmark investigation illuminates nicotinamide’s significant potential to reshape skin cancer chemoprevention strategies. By facilitating early intervention, particularly after a first diagnosis, nicotinamide may alter disease trajectories, improve patient quality of life, and reduce the global burden of skin cancer. As the scientific community continues to unravel the complexities of skin carcinogenesis and host defense, nicotinamide stands out as a promising agent bridging nutritional biochemistry and clinical oncology.

Subject of Research: Skin cancer chemoprevention using nicotinamide
Article Title: Nicotinamide for Skin Cancer Chemoprevention
News Publication Date: 17-Sep-2025
Web References: JAMA Dermatology Article DOI
Image Credits: Vanderbilt University Medical Center
Keywords: Skin cancer, Nicotinamides, Chemoprevention, Basal cell carcinoma, Squamous cell carcinoma, Vitamin B3, Nicotinamide adenine dinucleotide, Dermatology, Veterans Affairs

Nicotinamide, chemically known as niacinamide, is a form of vitamin B3 essential for vital cellular processes such as DNA repair and cellular energy metabolism. Its pharmacological properties include enhancing the skin’s ability to repair ultraviolet (UV) damage and reducing inflammation, both of which are established contributors to carcinogenesis in the integumentary system. These biochemical mechanisms provide a rational basis for the observed protective effects against skin malignancies in this longitudinal observational analysis.

The study employed rigorous cohort methodologies, following susceptible populations over an extended period to ascertain the incidence of skin cancer among subjects treated with nicotinamide compared to those without such intervention. Cohort studies offer significant strengths in establishing temporal relationships and risk factor associations, which are particularly relevant in preventive medicine and chemoprevention research fields. The longitudinal design provided robust data on medication adherence, dose-response relationships, and stratified outcomes based on clinical characteristics.

Importantly, the research highlights the preventative potential of nicotinamide within the realm of clinical oncology and dermatology, targeting an area marked by previously limited pharmacologic options. Topical and systemic agents for skin cancer prevention have traditionally faced challenges related to efficacy, safety, and accessibility. Nicotinamide’s over-the-counter availability and low toxicity profile make it an attractive candidate for widespread clinical implementation and population health strategies, particularly for high-risk cohorts such as individuals with a history of actinic keratosis or basal cell carcinoma.

From a pathophysiological perspective, skin carcinogenesis involves DNA photolesions primarily caused by UV radiation, leading to mutations in oncogenes and tumor suppressor genes. Nicotinamide enhances the skin cells’ capacity to repair UV-induced DNA damage, thereby reducing mutagenesis and subsequent tumor formation. Moreover, this vitamin B3 derivative modulates cellular inflammation and immunosuppression, both factors known to facilitate the skin’s malignant transformation.

The implications of this study extend beyond dermatology, touching on broader concepts of preventive medicine and public health. Integrating nicotinamide supplementation into standard care protocols could lead to reduced healthcare burdens associated with skin cancer treatments and improved patient quality of life. Effective chemoprevention tools are critical in an era of increasing environmental UV exposure and aging populations, where primary prevention remains a formidable challenge.

Editor in Chief of JAMA Dermatology, Dr. Kanade Shinkai, MD, PhD, recognized the manuscript as a vital contribution to medical literature and selected it as a highlight for journalistic dissemination. Anticipated media packages accompanying the publication will include a detailed podcast and short video, enabling broad accessibility and fostering public engagement around evidence-based skin cancer prevention strategies.

The study’s corresponding author, Dr. Lee Wheless, MD, PhD, can be contacted via email for further inquiries, underscoring a commitment to transparency and scientific dialogue. While the paper comprehensively addresses key aspects such as author contributions, conflicts of interest, and funding support, readers are encouraged to consult the full article upon its release for detailed methodology and data analysis.

The cohort findings align well with emerging evidence from prior randomized controlled trials investigating nicotinamide’s photoprotective properties. However, this research uniquely emphasizes its practical application in real-world clinical settings, demonstrating sustained risk reduction when used after initial skin cancer events—a critical insight for patient-specific preventive care models.

In the context of dermatology, these results may catalyze a paradigm shift in how clinicians approach secondary prevention of skin cancer. Integration of nicotinamide into routine care could complement existing strategies such as sun protection education and regular dermatologic surveillance, enhancing the overall efficacy of skin cancer management protocols.

In conclusion, this seminal study contributes significant knowledge to the field of chemo-prevention and reaffirms the therapeutic promise of vitamin-based interventions in oncology. Its dissemination is expected to influence clinical guidelines and inspire further research into nicotinamide and related compounds for disease prevention.

Subject of Research: Nicotinamide’s impact on skin cancer risk reduction

Article Title: Information not provided

News Publication Date: Information not provided

Web References: Embargoed access link not provided

References: DOI reference – 10.1001/jamadermatol.2025.3238

Image Credits: Information not provided

Keywords: Skin, Cancer, Chemoprevention, Dermatology, Medications, Cohort studies, Vitamin B, Risk factors, Disease prevention, Oncology